CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE
To conduct analysis of basal-bolus insulin detemir/aspart in comparison with the NPH/human insulin for the treatment of patients with diabetes mellitus type 1 in Russia. We evaluate results of PREDICTIVE study using pharmacoeconomic analyses: «cost — effectiveness», «cost — utility» and « budget impact». Analysis included the most widely known insulins: Protaphane®, Actrapid®, NovoRapid® and Levemir®. The period of analysis was 1 year. Additional costs for insulin transition (Protaphane® / Actrapid® to Levemir® / NovoRapid®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles. The reduced frequency of severe hypoglycemia (Levemir® /NovoRapid®) contributed to cost saving of 2954 rubles per 1 patient/year, which allows an additional treatment 18,0% of diabetic patients.